Note 11 - Business Segment Information (Tables)

6 Months Ended

Jun. 30, 2021

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three months ended June 30,						Six months ended June 30,
	2021			2020			2021			2020
Revenue
BioLargo corporate	$	—		$	—		$	7		$	—
ONM		318			299			638			596
BLEST		266			160			654			444
Water		—			—			9			—
Clyra Medical		—			21			114			21
Intersegment revenue		(120	)		(62	)		(387	)		(205	)
Total	$	464		$	418		$	1,035		$	856
Operating loss
BioLargo corporate	$	(937	)	$	(1,129	)	$	(1,860	)	$	(1,936	)
ONM		(107	)		(134	)		(283	)		(287	)
Clyra Medical		(300	)		(422	)		(739	)		(728	)
BLEST		(190	)		(124	)		(373	)		(331	)
Water		(168	)		(196	)		(305	)		(424	)
Total	$	(1,702	)	$	(2,005	)	$	(3,560	)	$	(3,706	)
Interest expense
BioLargo corporate	$	(51	)	$	(735	)	$	(106	)	$	(1,479	)
Clyra Medical		(38	)		(12	)		(76	)		(25	)
Total	$	(89	)	$	(747	)	$	(182	)	$	(1,504	)
Research and development expense
BioLargo corporate	$	(209	)	$	(119	)	$	(545	)	$	(321	)
Clyra Medical		(6	)		(47	)		(33	)		(61	)
BLEST		(123	)		(85	)		(228	)		(166	)
Water		(138	)		(137	)		(257	)		(317	)
Intersegment R&D		120			38			380			181
Total	$	(356	)	$	(350	)	$	(683	)	$	(684	)

As June 30, 2021	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	1,072	$	431	$	1,016	$	321	$	151	$	(47	)	$	2,944
Right of use		185		—		—		126		—		—			311
Investment in South Korean joint venture		40		—		—		—		—		—			40
Intangible assets		2,150		—		—		—		—		—			2,150

As of December 31, 2020	BioLargo		ONM		Clyra		BLEST		Water		Elimination			Total
Tangible assets	$	603	$	624	$	1,125	$	314	$	105	$	(42	)	$	2,388
Right of use		215		—		—		126		—		—			341
Investment in South Korean joint venture		63		—		—		—		—		—			63
Intangible assets		2,150		—		—		—		—		—			2,150